Last updated on March 2018

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B


Brief description of study

This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir.

Detailed Study Description

This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir. HBeAg-negative subjects will be randomized to receive low or high dose vaccine, in the presence or absence of IC31® adjuvant, or to receive placebo or IC31® adjuvant alone.

Clinical Study Identifier: NCT02496897

Contact Investigators or Research Sites near you

Start Over

Byoung Kuk Jang, MD

Keimyung University Dongsan Medical Center
Daegu, Korea, Republic of

Won Young Tak, MD

Kyungpook National University Hospital
Daegu, Korea, Republic of
0.97miles